Related Experiment Video
Updated: Aug 11, 2026

Electrophysiological Measurements and Analysis of Nociception in Human Infants
Published on: December 20, 2011
Salicylate toxicity associated with administration of Percy medicine in an infant
Teresa V Lewis1, Randal Badillo, Scott Schaeffer
1College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73190, USA. Teresa-Lewis@OUHSC.edu
Insights
Over-the-counter bismuth subsalicylate medication caused salicylate toxicity in an infant. Healthcare providers must educate the public on risks of pediatric use for nonprescription drugs.
Area of Science:
- Pediatric Toxicology
- Pharmacovigilance
- Gastroenterology
Background:
- Bismuth subsalicylate is an over-the-counter gastrointestinal medication.
- Salicylate-containing products are generally not recommended for infants under one year of age.
Observation:
- A 3-month-old infant developed severe salicylate toxicity, including central nervous system depression and metabolic acidosis, after receiving bismuth subsalicylate for colic.
- The infant required pediatric intensive care unit (PICU) admission and treatment, including whole bowel irrigation and alkalinization therapy.
Findings:
- The infant's parents administered the medication without prior knowledge of its aspirin equivalency (57-84 mg/kg/day).
- Serum salicylate levels reached 747 mg/L, indicating significant toxicity.
Implications:
- This case highlights the potential dangers of over-the-counter medications in infants and the importance of reading labels.
- Healthcare professionals play a crucial role in educating the public about the safe use of nonprescription drugs in children.
- Increased awareness and caution are needed regarding pediatric dosing of salicylate-containing products.
Abstract:
Percy Medicine is a nonprescription gastrointestinal suspension containing bismuth subsalicylate as the active ingredient (1050 mg/10-ml dose). A 3-month-old infant with colic developed salicylate toxicity requiring hospitalization in the pediatric intensive care unit (PICU) as a result of continued administration of this medicine. Bismuth subsalicylate has an aspirin equivalency conversion factor of 0.479 (approximately half the strength of aspirin). For 3.5 weeks the infant's parents administered the medicine, which provided the equivalent of aspirin 57-84 mg/kg/day with no reported problems. However, on the day of admission the baby presented with central nervous system depression and respiratory distress. Assessment at a local emergency facility revealed metabolic acidosis; his serum salicylate concentration was 747 mg/L. After acute management, the patient was transferred to our hospital, where he was treated with whole bowel irrigation and alkalinization therapy. Subsequently, the baby required 4 days of management in the PICU and 2 additional days of observation in a general nursing unit before he was discharged home without incident. The parents had chosen Percy Medicine based on the picture of a baby on the front of the package and because of its placement on the shelf next to a drug their family physician had recommended previously. Salicylate-containing products are not routinely recommended for children aged 1 year or younger. The general public may assume that over-the-counter products are safe because they do not require a prescription. Health care professionals must be responsible for educating the public regarding risks associated with over-the-counter products and the need to read and follow label directions.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Factors Affecting Drug Response: Overview
Prevention of Further Absorption of Poison
Pharmaceutical Poisoning: Potential Scenarios
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Drug toxicity: Drug–Drug Interaction
